For research use only. Not for therapeutic Use.
HS-173 (Cat No.:I001100) is a novel PI3K (phosphoinositide 3-kinase) inhibitor that has shown potential for cancer treatment. PI3K is a key enzyme involved in cell growth, survival, and proliferation, and its dysregulation is frequently observed in various cancers. HS-173 selectively inhibits PI3K activity, leading to the suppression of downstream signaling pathways involved in tumor growth and progression. Preclinical studies have demonstrated the anticancer efficacy of HS-173 in various cancer types, including breast, lung, colon, and prostate cancers. HS-173 holds promise as a targeted therapy for PI3K-driven cancers and may contribute to the development of novel cancer treatments.
| Catalog Number | I001100 |
| CAS Number | 1276110-06-5 |
| Molecular Formula | C21H18N4O4S |
| Purity | ≥95% |
| Target | PI3K |
| Solubility | DMSO: ≥ 30 mg/mL |
| Storage | Desiccate at -20C |
| IUPAC Name | ethyl 6-[5-(benzenesulfonamido)pyridin-3-yl]imidazo[1,2-a]pyridine-3-carboxylate |
| InChI | InChI=1S/C21H18N4O4S/c1-2-29-21(26)19-13-23-20-9-8-15(14-25(19)20)16-10-17(12-22-11-16)24-30(27,28)18-6-4-3-5-7-18/h3-14,24H,2H2,1H3 |
| InChIKey | SEKOTFCHZNXZMM-UHFFFAOYSA-N |
| SMILES | CCOC(=O)C1=CN=C2N1C=C(C=C2)C3=CC(=CN=C3)NS(=O)(=O)C4=CC=CC=C4 |
| Reference | </br>1:HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Rumman M, Jung KH, Fang Z, Yan HH, Son MK, Kim SJ, Kim J, Park JH, Lim JH, Hong S, Hong SS.Oncotarget. 2016 Nov 22;7(47):78029-78047. doi: 10.18632/oncotarget.12871. PMID: 27793006 Free PMC Article</br>2:HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis. Son MK, Ryu YL, Jung KH, Lee H, Lee HS, Yan HH, Park HJ, Ryu JK, Suh JK, Hong S, Hong SS.Sci Rep. 2013 Dec 11;3:3470. doi: 10.1038/srep03470. PMID: 24326778 Free PMC Article</br>3:Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Yun SM, Jung KH, Lee H, Son MK, Seo JH, Yan HH, Park BH, Hong S, Hong SS.Cancer Lett. 2013 May 1;331(2):250-61. doi: 10.1016/j.canlet.2013.01.007. Epub 2013 Jan 20. PMID: 23340175 </br>4:HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Lee H, Jung KH, Jeong Y, Hong S, Hong SS.Cancer Lett. 2013 Jan 1;328(1):152-9. doi: 10.1016/j.canlet.2012.08.020. Epub 2012 Aug 26. PMID: 22929971 |
